AMRX — Amneal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $6.70bn
- $9.39bn
- $3.02bn
U.S. STOCKS ON THE MOVE-3M, VF Corp, SiriusXM
U.S. STOCKS ON THE MOVE-Howmet Aerospace, Alaska Air, Arcus Biosciences
Brief: Amneal Receives U.S. FDA Approval Of New Drug Application For Pyridostigmine Bromide Extended-Release Tablets
Amneal rises as US FDA approves pretreatment for nerve agent poisoning
Amneal asks court to block Colorado's free allergy pen program
Brief: Amneal Launches Crexont® (Carbidopa And Levodopa) Extended-Release Capsules For Treatment Of Parkinson’S Disease
U.S. STOCKS ON THE MOVE-Stericycle, Oil companies, US Banks
U.S. STOCKS ON THE MOVE-DocuSign, U.S homebuilders, Texas Capital Bancshares
U.S. STOCKS ON THE MOVE-Smartsheet, Bowlero, Samsara
Amneal rises after J.P. Morgan upgrades to 'neutral' on strength in generics unit
U.S. RESEARCH ROUNDUP- Broadcom, Costco Wholesale, Saia
Brief: Amneal And Shilpa Announce U.S. FDA Approval Of Boruzu™
Brief: Amneal Receives FDA Approval for Propofol Injectable Emulsion Single Dose Vials
U.S. STOCKS ON THE MOVE-Revance Therapeutics, Insulet, StepStone
U.S. STOCKS ON THE MOVE-Synchrony, Grindr, Blend Labs
Amneal Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Amneal Pharmaceuticals rises on annual revenue forecast raise
Brief: Amneal Says Raising 2024 Full Year Guidance
Brief: Amneal Pharmaceuticals Says Crexont Commercial Launch Planned In September 2024